Repair	1
Spinal Cord Injury	11
Co-Transplantation of embryonic Stem Cell-Derived Motor Neuron	33
Co-Transplantation	33
embryonic Stem Cell-Derived Motor Neuron	55
Olfactory Ensheathing Cell ABSTRACT Background	100
Olfactory Ensheathing Cell	100
ABSTRACT Background	128
The failure of regeneration after spinal cord injury -LRB- SCI -RRB-	149
The failure	149
regeneration after spinal cord injury -LRB- SCI -RRB-	164
regeneration	164
spinal cord injury -LRB- SCI -RRB-	183
spinal cord injury	183
SCI	203
axonal demyelination and neuronal death	231
axonal demyelination	231
neuronal death	256
Cellular replacement and white matter regeneration	272
Cellular replacement	272
white matter regeneration	297
SCI repair	346
this study	361
we	373
the co-transplantation	386
olfactory ensheathing cells -LRB- OEC -RRB- and embryonic stem -LRB- ES -RRB-	412
olfactory ensheathing cells	412
OEC	441
embryonic stem	450
ES	466
cell-derived motor neurons	470
ESMN	498
contused SCI	507
Methods : OEC cultured from olfactory nerve rootlets and olfactory bulbs .	521
Methods	521
OEC cultured from olfactory nerve rootlets and olfactory bulbs	530
OEC	530
olfactory nerve rootlets and olfactory bulbs	548
olfactory nerve rootlets	548
olfactory bulbs	577
ESMN	594
mouse ES cells	625
retinoic acid and sonic hedgehog	643
retinoic acid	643
sonic hedgehog	661
Thirty female rats	677
SCI models	717
five groups	731
Control and mediuminjected groups	744
Control	744
mediuminjected groups	756
lesion	802
cell transplantation	817
OEC or ESMN or both	839
OEC or ESMN	839
both	854
the site of the lesion in other groups	882
the site	882
the lesion in other groups	894
the lesion	894
other groups	908
Results : The purity of OEC culture was 95 % .	922
Results	922
The purity of OEC culture	931
The purity	931
OEC culture	945
95 %	961
Motor neuron progenitor markers -LRB- Olig2 , Nkx6 .1 and Pax6 -RRB-	966
Motor neuron progenitor markers	966
Olig2 , Nkx6 .1 and Pax6	999
Olig2	999
Nkx6 .1 and Pax6	1006
motor neuron markers -LRB- Isl1 , Isl2 and Hb9 -RRB-	1027
motor neuron markers	1027
Isl1 , Isl2 and Hb9	1049
Isl1	1049
Isl2 and Hb9	1055
Histological analysis	1085
significantly more -LRB- P < 0.001 -RRB- spinal tissue	1119
P < 0.001	1139
P	1139
< 0.001	1140
<	1140
0.001	1141
OEC , ESMN and OEC	1176
+ ESMN groups but the OEC + ESMN group	1193
ESMN groups	1195
the OEC + ESMN group	1211
a significantly greater percentage	1235
spared tissue and myelination than other groups -LRB- P < 0.05 -RRB-	1273
spared tissue and myelination	1273
other groups -LRB- P < 0.05 -RRB-	1308
other groups	1308
P < 0.05	1322
P	1322
< 0.05	1323
<	1323
0.05	1325
The numbers of ESMN in co-transplanted group	1332
The numbers	1332
ESMN in co-transplanted group	1347
ESMN	1347
co-transplanted group	1355
ESMN group	1408
P < 0.05	1420
P	1420
< 0.05	1421
<	1421
0.05	1422
A significant -LRB- P < 0.05 -RRB- recovery of hindlimb function	1429
A significant -LRB- P < 0.05 -RRB- recovery	1429
P < 0.05	1444
P	1444
< 0.05	1445
<	1445
0.05	1446
hindlimb function	1464
rats in the transplanted groups	1498
rats	1498
the transplanted groups	1506
Conclusion	1531
We	1543
the co-transplantation of ESMN and OEC into an injured spinal cord	1557
the co-transplantation	1557
ESMN and OEC into an injured spinal cord	1583
ESMN and OEC	1583
an injured spinal cord	1601
a synergistic effect	1628
neural regeneration , ESMN survival and partial functional recovery	1660
neural regeneration	1660
ESMN survival	1681
partial functional recovery	1699
INTRODUCTION The long-term effects of spinal cord injuries -LRB- SCI -RRB-	1729
INTRODUCTION The long-term effects of spinal cord injuries	1729
INTRODUCTION	1729
The long-term effects of spinal cord injuries	1742
The long-term effects	1742
spinal cord injuries	1767
SCI	1789
the life of the patient	1812
the life	1812
the patient	1824
The main goal of basic SCI research	1837
The main goal	1837
basic SCI research	1854
new therapeutic interventions	1887
disability	1959
One of the major strategies to regenerate spinal cord	1971
One	1971
the major strategies to regenerate spinal cord	1978
spinal cord	2013
cellular transplantation	2028
The aim of cell therapy	2054
The aim	2054
cell therapy	2065
dead cells , remyelinate axons	2092
a favorable environment for axon regeneration	2138
a favorable environment	2138
axon regeneration	2166
Numerous studies	2185
the therapeutic potential of cellular transplants of various types	2217
the therapeutic potential	2217
cellular transplants of various types	2246
cellular transplants	2246
various types	2270
white matter regeneration -LSB- 1-3 -RSB-	2288
white matter regeneration	2288
1-3 -RSB-	2315
Olfactory ensheathing cell -LRB- OEC -RRB-	2321
Olfactory ensheathing cell	2321
OEC	2349
a specialized glial cell	2357
the olfactory nerve	2404
the sensory axons	2437
an array	2467
trophic factors	2479
transcription factors	2496
extracellular matrix molecules -LSB- 4-6 -RSB-	2523
extracellular matrix molecules	2523
4-6 -RSB-	2555
Combination of these properties	2561
Combination	2561
these properties	2576
OEC	2598
a candidate for spinal cord repair -LSB- 7-9 -RSB-	2602
a candidate	2602
spinal cord repair -LSB- 7-9 -RSB-	2618
spinal cord repair	2618
7-9 -RSB-	2638
The degeneration of motor neurons after SCI	2644
The degeneration	2644
motor neurons after SCI	2664
motor neurons	2664
SCI	2684
cell replacement strategies	2707
stem cell-derived motor neurons	2741
-LSB- 10 , 11 -RSB-	2773
Embryonic stem -LRB- ES -RRB- cells	2783
Embryonic stem	2783
ES	2799
several features that include replicating indefinitely without aging	2814
several features	2814
aging	2877
pluripotency	2884
rise to all different cell types in the body	2905
rise	2905
all different cell types in the body	2913
all different cell types	2913
the body	2941
12 -RSB-	2951
A multitude	2956
differentiation protocols	2980
specific neuronal and glial subtypes	3024
ES cells	3066
Spinal motor neurons and interneurons	3096
mouse ES cells	3180
retinoic acid -LRB- RA -RRB- and sonic hedgehog -LRB- Shh -RRB-	3198
retinoic acid	3198
RA	3213
sonic hedgehog	3221
Shh	3237
Some studies	3243
the potential of ES cells	3271
the potential	3271
ES cells	3288
spinal motor neuron degeneration	3307
function	3352
animals with SCI -LSB- 2 , 6 -RSB-	3364
animals	3364
SCI -LSB- 2 , 6 -RSB-	3377
embryonic stem -LRB- ES -RRB- cell-derived motor neurons -LRB- ESMN -RRB-	3398
embryonic stem -LRB- ES -RRB- cell-derived motor neurons	3398
embryonic stem	3398
ES	3414
cell-derived motor neurons	3418
ESMN	3446
transplantation	3452
spinal cord repair	3496
the majority of the ESMN	3523
the majority	3523
the ESMN	3539
the spinal cord	3563
the present study	3611
the first time	3634
we	3650
the potential use of co-transplantation of OEC and ESMN	3666
the potential use	3666
co-transplantation of OEC and ESMN	3687
co-transplantation	3687
OEC and ESMN	3709
a therapeutic strategy in spinal cord injured rats	3725
a therapeutic strategy	3725
spinal cord injured rats	3751
spinal cord	3751
rats	3771
MATERIALS AND METHODS	3778
Animals	3800
Adult female Wistar rats -LRB- n = 40 , aged 6-8 weeks and 250-300 g -RRB-	3809
Adult female Wistar rats	3809
n = 40 , aged 6-8 weeks and 250-300 g	3835
n = 40	3835
n	3835
40	3839
6-8 weeks and 250-300 g	3848
6-8 weeks	3848
250-300 g	3862
the Razi Vaccine and Serum Research Institute , Karaj , Iran	3892
the Razi Vaccine	3892
Serum Research Institute , Karaj , Iran	3913
Serum Research Institute	3913
Karaj , Iran	3939
The animals	3952
a 12 hour dark/light cycle	3983
20 Â°C	4013
Food and water	4019
Food	4019
water	4028
proportioned ad libitum	4038
All experimental procedures	4063
the Animal Care and Ethics	4108
the Animal Care	4108
Ethics	4128
Tehran University of Medical Sciences , Tehran , Iran	4138
Tehran University	4138
Medical Sciences , Tehran , Iran	4159
Medical Sciences	4159
Tehran , Iran	4177
SCI	4204
we	4209
30 rats in the following five groups -LRB- 6 rats in each group -RRB-	4217
30 rats	4217
the following five groups -LRB- 6 rats in each group -RRB-	4228
the following five groups	4228
6 rats in each group	4255
6 rats	4255
each group	4265
control group	4278
lesion induction without cellular transplantation	4293
lesion induction	4293
cellular transplantation	4318
medium-injected group , lesion induction and medium injection	4344
medium-injected group	4344
lesion induction	4367
medium injection	4388
OEC group , lesion induction and transplantation of OEC	4406
OEC group	4406
lesion induction and transplantation of OEC	4417
lesion induction and transplantation	4417
OEC	4457
ESMN group , lesion induction and transplantation of ESMN	4462
ESMN group	4462
lesion induction and transplantation of ESMN	4474
lesion induction and transplantation	4474
ESMN	4514
OEC + ESMN group	4532
OEC	4532
ESMN group	4538
lesion induction and co-transplantation of OEC and ESMN	4550
lesion induction and co-transplantation	4550
OEC and ESMN	4593
We	4607
10 rats	4620
OEC culture	4632
OEC cell culture .	4645
OEC	4645
cell culture	4649
establishment of OEC	4667
establishment	4667
OEC	4684
we	4689
Nash -LSB- 13 -RSB- methods	4697
Nash -LSB-	4697
some modifications -LSB- 14 -RSB-	4720
some modifications	4720
14 -RSB-	4740
brief	4748
rats	4755
overdose of ketamine and xylazine	4783
overdose	4783
ketamine and xylazine	4795
decapitation	4831
A skin incision	4845
the scalp extending from the tip of the nose to the occipital bone of the skull	4873
the scalp	4873
the tip of the nose	4898
the tip	4898
the nose	4909
the occipital bone of the skull	4921
the occipital bone	4921
the skull	4943
the nasal and frontal bones	4957
The olfactory nerve rootlets and olfactory bulbs	4999
The olfactory nerve rootlets	4999
olfactory bulbs	5032
chilled calcium	5076
magnesium free Hank 's balanced salt solution -LRB- HBSS , Sigma -RRB-	5096
magnesium	5096
free Hank 's balanced salt solution -LRB- HBSS , Sigma -RRB-	5106
free Hank 's balanced salt solution	5106
free Hank 's	5106
HBSS	5142
Sigma	5148
The tissue	5156
all meninges and blood vessels	5183
The outer two layers of the olfactory bulb and the olfactory nerve	5215
The outer two layers	5215
the olfactory bulb and the olfactory nerve	5239
the olfactory bulb	5239
the olfactory nerve	5262
The tissues	5311
a solution of 0.25 % collagenase type IA and dispase	5356
a solution	5356
0.25 % collagenase type IA and dispase	5370
II	5408
2.4 U/ml in Puck s solution ; Roche Diagnostics , Mannheim , Germany	5412
2.4 U/ml	5412
Puck s solution ; Roche Diagnostics , Mannheim , Germany	5424
Puck s solution	5424
Roche Diagnostics , Mannheim , Germany	5441
Roche Diagnostics	5441
Mannheim , Germany	5460
DMEM/F12 -LRB- Gibco , USA -RRB- in 5 % CO2 at 37 Â°C for 30 minutes	5482
DMEM/F12 -LRB- Gibco , USA -RRB-	5482
DMEM/F12	5482
Gibco	5492
USA	5499
5 % CO2 at 37 Â°C for 30 minutes	5507
5 % CO2	5507
37 Â°C for 30 minutes	5517
37 Â°C	5517
30 minutes	5526
The tissue	5538
the dispase and collagenase activity	5595
HBSS	5654
The cell suspensions	5660
300 Ã g for 5 minutes	5706
300 Ã g	5706
5 minutes	5717
plastic cell culture flask	5743
Gibco	5783
USA	5790
10 % fetal bovine serum -LRB- FBS , Sigma -RRB-	5806
10 % fetal bovine serum	5806
FBS	5830
Sigma	5835
2 mM Lglutamine -LRB- Gibco , USA -RRB-	5843
2 mM Lglutamine	5843
Gibco	5860
USA	5867
100 IU/ml penicillin	5873
100 Î¼g/ml streptomycin -LRB- Gibco , USA -RRB-	5898
100 Î¼g/ml streptomycin	5898
Gibco	5922
USA	5929
Cultures	5935
37ÂºC	5957
a humidified atmosphere containing 95 % air and 5 % CO2 for 18 hours	5965
a humidified atmosphere	5965
95 % air and 5 % CO2 for 18 hours	6000
95 % air	6000
5 % CO2 for 18 hours	6012
5 % CO2	6012
18 hours	6023
Most of the fibroblasts and fibroblast-like cells	6033
Most	6033
the fibroblasts and fibroblast-like cells	6041
the fibroblasts	6041
fibroblast-like cells	6061
plate	6095
this first incubation period	6108
The supernatants from the culture	6138
The supernatants	6138
the culture	6160
a second set of uncoated culture flasks	6199
a second set	6199
uncoated culture flasks	6215
36 hours of incubation	6246
36 hours	6246
incubation	6258
most of the OEC	6270
most	6270
the OEC	6278
the supernatant	6298
This supernatant	6315
seed a set of poly-L-lysine -LRB- Sigma -RRB- flasks	6344
seed a set	6344
seed	6344
a set	6349
poly-L-lysine -LRB- Sigma -RRB- flasks	6358
poly-L-lysine -LRB- Sigma -RRB-	6358
poly-L-lysine	6358
Sigma	6373
flasks	6380
the OEC	6403
48 hours	6427
Cultures	6437
appropriate cell number	6462
the media	6503
every 2 days	6526
ES cell culture and differentiation .	6540
ES cell	6540
culture and differentiation	6548
ESMN	6577
previously published method using feeder-free GFP-positive CGR8 mouse ES cells	6595
previously published method	6595
feeder-free GFP-positive CGR8 mouse ES cells	6629
a Gift from Stem cells Technology	6675
a Gift	6675
Stem cells Technology	6687
Tehran , Iran	6710
Tehran	6710
Iran	6718
10 -RSB-	6725
ES cells	6730
plate	6765
ES culture medium	6774
KoDMEM	6802
Gibco	6810
USA	6817
1 % nonessential amino acids -LRB- Gibco , USA -RRB-	6840
1 % nonessential amino acids	6840
Gibco	6869
USA	6876
0.1 mM 2-mercaptoethanol -LRB- Sigma , USA -RRB-	6882
0.1 mM 2-mercaptoethanol	6882
Sigma	6908
USA	6915
2 mM L-Glutamine -LRB- Gibco , USA -RRB-	6921
2 mM L-Glutamine	6921
Gibco	6939
USA	6946
1 % Penicillin/Streptomycin -LRB- Gibco , USA -RRB-	6952
1 % Penicillin/Streptomycin	6952
Gibco	6980
USA	6987
10 % ES FBS -LRB- Gibco , USA -RRB-	6993
10 % ES FBS	6993
Gibco	7005
USA	7012
1000 Î¼/ml LIF -LRB- ESGRO , Chemi - Con -RRB-	7021
1000 Î¼/ml LIF	7021
ESGRO , Chemi - Con	7036
ESGRO	7036
Chemi - Con	7043
Chemi	7043
Con	7050
ES cell colonies	7062
DFK5 medium	7112
DFK5 medium	7125
DF medium	7160
DMEM/F12	7171
2 mM L-Glutamine	7198
1 % Penicillin/Streptomycin	7216
0.1 mM 2-mercaptoethanol	7243
1 % Insulin-Trasferrin-Selenium Supplement -LRB- Gibco , USA -RRB-	7269
1 %	7269
Insulin-Trasferrin-Selenium Supplement -LRB- Gibco , USA -RRB-	7271
Insulin-Trasferrin-Selenium Supplement	7271
Gibco	7311
USA	7318
a 1:1 ratio	7327
ES medium -LRB- ES cell medium without LIF and FBS	7344
ES medium -LRB- ES cell medium without LIF	7344
ES medium	7344
ES cell medium without LIF	7355
ES cell medium	7355
LIF	7378
FBS	7386
10 % Knockout Serum Replacement -LRB- Gibco , USA -RRB- -RSB-	7412
Gibco	7444
USA	7451
Embryoid Body -LRB- EB -RRB-	7465
Embryoid Body	7465
EB	7480
Medium	7485
DFK5	7508
RA -LRB- 1 Î¼M -RRB- and Shh -LRB- 300 nM , both from Sigma , USA -RRB-	7531
RA	7531
1 Î¼M	7535
Shh	7545
300 nM , both from Sigma , USA	7550
300 nM , both	7550
300 nM	7550
Sigma , USA	7568
EB	7584
4 days	7605
EB	7613
gelatin coated flasks	7647
serum-free DMEM/F12 medium supplemented with 1 % N2 -LRB- Gibco , USA -RRB-	7672
serum-free DMEM/F12 medium	7672
1 % N2 -LRB- Gibco , USA -RRB-	7717
1 % N2	7717
Gibco	7724
USA	7731
longer culture	7741
they	7757
3 days	7785
Neurobasal medium plus 2 % B27 supplement -LRB- Gibco , USA -RRB- and 10 % FBS	7795
Neurobasal medium plus 2 % B27 supplement -LRB- Gibco , USA -RRB-	7795
Neurobasal medium	7795
2 % B27 supplement -LRB- Gibco , USA -RRB-	7818
2 % B27 supplement	7818
Gibco	7837
USA	7844
10 % FBS	7853
Immunocytochemistry .	7862
The cells	7883
incubation in 4 % paraformaldehyde -LRB- Sigma , USA -RRB-	7907
incubation	7907
4 % paraformaldehyde -LRB- Sigma , USA -RRB-	7921
4 % paraformaldehyde	7921
Sigma	7942
USA	7949
The fixed cells	7955
PBS	7988
0.1 % Triton X-100 -LRB- Sigma , USA -RRB-	8015
0.1 % Triton X-100	8015
Sigma	8034
USA	8041
PBS	8049
buffer	8078
PBS , 1 mg/ml BSA -LRB- Sigma , USA -RRB- and 10 % goat serum -LRB- Gibco , USA	8086
PBS	8086
1 mg/ml BSA -LRB- Sigma , USA -RRB-	8091
1 mg/ml BSA	8091
Sigma	8104
USA	8111
10 % goat serum -LRB- Gibco , USA	8120
10 % goat serum	8120
Gibco	8136
USA	8143
incubation	8160
primary antibodies at 4 Â°C overnight	8176
primary antibodies	8176
4 Â°C overnight	8198
4 Â°C	8198
Cells	8213
PBS	8241
a species-specific secondary antibody	8264
Cultures	8303
three changes of PBS	8329
three changes	8329
PBS	8346
nucleus	8354
4	8377
fluorescent microscope	8425
The expression of p75 lowaffinity nerve growth factor receptor in OEC culture	8449
The expression	8449
p75 lowaffinity nerve growth factor receptor in OEC culture	8467
p75 lowaffinity nerve growth factor receptor	8467
OEC culture	8515
immunostaining	8545
the cells	8560
primary monoclonal mouse anti-p75 NGFR antibody -LRB- Sigma , USA -RRB-	8575
primary monoclonal mouse	8575
anti-p75 NGFR antibody -LRB- Sigma , USA -RRB-	8600
anti-p75 NGFR antibody	8600
Sigma	8624
USA	8631
secondary FITC-conjugated antimouse IgG antibody -LRB- Abcam , USA -RRB-	8640
secondary FITC-conjugated antimouse	8640
IgG antibody -LRB- Abcam , USA -RRB-	8676
IgG antibody	8676
Abcam	8690
USA	8697
The expression	8703
microtubule assassination protein 2 -LRB- MAP2 -RRB-	8721
tubulin Î²III in differentiated mouse ES cells	8768
tubulin Î²III	8768
mouse ES cells	8799
immunostaining	8832
the cells	8847
primary monoclonal mouse anti-MAP2 and tubulin Î²III	8862
Sigma	8915
USA	8922
secondary phycoerythrinconjugated anti-mouse IgG antibody	8931
Abcam	8990
USA	8997
RNA extraction and RT-PCR analysis of gene expression .	9003
RNA extraction and RT-PCR analysis	9003
gene expression	9041
Total RNA	9058
cells using the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9086
cells	9086
the RNX plus kit -LRB- Cinnagen , Iran -RRB-	9098
the RNX	9098
kit -LRB- Cinnagen , Iran -RRB-	9111
kit	9111
Cinnagen	9116
Iran	9126
Standard RT	9133
the Revert AidTM H Minus First Strand cDNA Synthesis Kit -LRB- Fermentas -RRB-	9165
the Revert AidTM H Minus First Strand cDNA Synthesis Kit	9165
the Revert AidTM H	9165
Minus First Strand cDNA Synthesis Kit	9184
Fermentas	9223
the manufacturer 's instructions	9247
the manufacturer 's	9247
PCR	9280
94 Â°C for 1 minute	9302
94 Â°C	9302
1 minute	9311
30 cycles of 94 Â°C for 30 s	9333
30 cycles	9333
94 Â°C for 30 s	9346
94 Â°C	9346
30 s	9355
55-63 Â°C for 30 s , 72 Â°C for 30 s and 72 Â°C for 10 minutes	9361
55-63 Â°C for 30 s	9361
55-63 Â°C	9361
30 s	9373
72 Â°C for 30 s	9379
72 Â°C	9379
30 s	9388
72 Â°C for 10 minutes	9397
72 Â°C	9397
10 minutes	9406
DNA fragments	9428
1.5 % agarose gel and the gels	9466
1.5 % agarose gel	9466
the gels	9487
ethidium bromide -LRB- 10 Î¼g/ml -RRB-	9514
ethidium bromide	9514
10 Î¼g/ml	9532
a UV transilluminator -LRB- Uvidoc , UK -RRB-	9562
a UV transilluminator	9562
Uvidoc	9585
UK	9593
The primers	9598
Table 1	9624
Surgical procedures .	9633
Surgical	9633
procedures	9642
SCI	9654
Vanicky 's method -LSB- 15 -RSB-	9676
Vanicky 's method	9676
Vanicky 's	9676
15 -RSB-	9694
brief	9702
adult female Wistar rats	9709
intraperitoneal injections	9757
ketamine -LRB- 50 mg/kg -RRB- and xylazine -LRB- 5 mg/kg -RRB-	9787
ketamine	9787
50 mg/kg	9797
xylazine	9811
5 mg/kg	9821
The spinous processes of vertebrae T10-T11	9831
The spinous processes	9831
vertebrae T10-T11	9856
a small hole -LRB- 2 mm diameter -RRB-	9891
a small hole	9891
2 mm diameter	9905
vertebral arch of T10	9935
vertebral arch	9935
T10	9953
A 2-French Fogarty catheter -LRB- Percuse , France -RRB-	9958
A 2-French Fogarty catheter	9958
Percuse	9987
France	9996
the epidural space	10022
the center of the balloon	10072
the center	10072
the balloon	10086
T8-T9 level	10108
The balloon	10121
20 Î¼l saline for 5 minutes	10159
20 Î¼l saline	10159
5 minutes	10176
Catheter	10187
the muscles and skin	10208
All rats	10238
antibiotic -LRB- cefazolin 50 mg/kg -RRB-	10256
antibiotic	10256
cefazolin 50 mg/kg	10268
cefazolin	10268
50 mg/kg	10278
analgesic -LRB- acetaminophen 1-2 mg/ml in drinking water -RRB-	10292
analgesic	10292
acetaminophen 1-2 mg/ml in drinking water	10303
acetaminophen 1-2 mg/ml	10303
drinking water	10330
Bladder expression	10347
two times per day	10380
two times	10380
day	10394
Urinary tract infections	10399
suspension of cefazolin	10442
suspension	10442
cefazolin	10456
12 mg/kg gentamicin	10473
Autophagia	10494
acetaminophen -LRB- 1-2 mg/ml -RRB- in drinking water	10522
acetaminophen -LRB- 1-2 mg/ml -RRB-	10522
acetaminophen	10522
1-2 mg/ml	10537
drinking water	10551
self-mutilation	10574
Hoechst	10591
OEC	10609
37 Â°C	10631
30 minutes	10640
cultured medium	10666
10 Î¼g/ml	10693
Hoechst 33342 -LRB- Sigma , USA -RRB-	10702
Hoechst 33342	10702
Sigma	10717
USA	10724
transplantation	10736
-LSB- 1 , 16	10752
they	10767
several times with DMEM	10784
several times	10784
DMEM	10803
serum	10816
the same medium	10838
the spinal cord	10876
Transplantations	10910
9 days	10942
the injury -LSB- 17 -RSB-	10955
the injury	10955
17 -RSB-	10967
All animals	10972
cyclosporine -LRB- 10 mg/kg , SC -RRB-	10998
cyclosporine	10998
10 mg/kg , SC	11012
10 mg/kg	11012
SC	11022
day 8 for immunosuppression	11029
day 8	11029
immunosuppression	11039
duration of survival	11075
duration	11075
survival	11087
18 -RSB-	11097
Rats	11102
DMEM medium in medium-injected group	11116
DMEM medium	11116
medium-injected group	11131
transplants of OEC -LRB- 1 Ã 106 -RRB- in OEC group	11154
transplants	11154
OEC -LRB- 1 Ã 106 -RRB- in OEC group	11169
OEC -LRB- 1 Ã 106 -RRB-	11169
OEC	11169
1 Ã 106	11174
1 Ã	11174
106	11178
OEC group	11186
ESMN -LRB- 1 Ã 106 -RRB- in ESMN group	11197
ESMN -LRB- 1 Ã 106 -RRB-	11197
ESMN	11197
1 Ã 106	11203
1 Ã	11203
106	11207
ESMN group	11215
OEC and ESMN -LRB- each 1 Ã 106 -RRB- in OEC	11231
OEC and ESMN -LRB- each 1 Ã 106 -RRB-	11231
OEC and ESMN	11231
each 1 Ã 106	11245
each 1 Ã	11245
106	11254
OEC	11263
ESMN group	11269
means of 5 Î¼L Hamilton syringe	11283
means	11283
5 Î¼L Hamilton syringe	11292
5 Î¼L	11292
The ESMN and OEC suspension -LRB- 5 Î¼l -RRB- or DMEM medium -LRB- 5 Î¼l -RRB-	11315
The ESMN and OEC suspension -LRB- 5 Î¼l -RRB-	11315
The ESMN and OEC suspension	11315
5 Î¼l	11344
DMEM medium -LRB- 5 Î¼l -RRB-	11353
DMEM medium	11353
5 Î¼l	11366
the center of the syrinx	11390
the center	11390
the syrinx	11404
T9 level over a 5-minute period	11418
T9 level	11418
a 5-minute period	11432
transplantation	11457
muscles and skin	11474
rats	11507
antibiotic	11521
Locomotor function .	11533
Locomotor	11533
function	11543
Locomotor function	11553
the Basso , Beattie and Bresnahan -LRB- BBB -RRB- open-field locomotor test	11592
Basso , Beattie and Bresnahan -LRB- BBB -RRB-	11596
Basso , Beattie and Bresnahan	11596
BBB	11626
two independent observers -LSB- 19 -RSB-	11663
two independent observers	11663
19 -RSB-	11690
BBB assessments	11695
3 days	11726
injury	11739
prior to transplantation and 7 , 14 , 21 and 28 days post transplantation	11750
transplantation and 7 , 14 , 21 and 28 days	11759
Histological evaluation .	11823
the final behavioral assessment post transplantation at 28 days	11854
the final behavioral assessment post transplantation	11854
28 days	11910
rats	11919
0.1 M PBS followed by 4 % paraformaldehyde and 2.5 % glutaraldehyde in PBS	11982
0.1 M PBS	11982
4 % paraformaldehyde and 2.5 % glutaraldehyde	12004
4 % paraformaldehyde	12004
2.5 % glutaraldehyde	12028
PBS	12051
The spinal cords	12056
10 % sucrose	12118
The cords	12131
TissueTek OCT compound	12160
Serial 12 Î¼m thick longitudinal sections	12184
Î¼m	12194
a cryostat	12237
Poly-LLysine coated slides	12263
The slides	12291
cresyl violet-Luxol	12318
blue and silver nitrate -LRB- both from Merck , Germany -RRB-	12343
blue and silver nitrate	12343
both from Merck , Germany	12368
both	12368
Merck , Germany	12378
morphometry and cell counting	12399
sections	12430
digital camera	12456
The identified areas in individual sections	12472
The identified areas	12472
individual sections	12496
image analysis software -LRB- Image J , NIH -RRB-	12536
image analysis software	12536
Image J	12561
NIH	12570
cell counts	12587
we	12600
the number	12611
transplanted cells	12625
the longitudinal sections as Hoechst-labeled and GFP-positive cells	12647
the longitudinal sections	12647
Hoechst-labeled and GFP-positive cells	12676
OEC , ESMN and OEC + ESMN groups	12718
OEC	12718
ESMN	12723
OEC + ESMN groups	12732
fluorescent microscope	12758
Every other six slides	12782
the cell count	12823
50 slides in each animal	12855
50 slides	12855
each animal	12868
Every ten longitudinal section	12881
the spared tissue and myelinated area	12934
the spared tissue	12934
myelinated area	12956
each section	12976
the number	12990
pixel	13004
area and the total number of pixels in spinal cord segment	13036
area	13036
the total number of pixels in spinal cord segment	13045
the total number	13045
pixels in spinal cord segment	13065
pixels	13065
spinal cord segment	13075
Measurements from each section	13110
Measurements	13110
each section	13128
rat	13157
the total number of sections	13179
the total number	13179
sections	13199
Spared spinal tissue	13209
the difference	13251
the numbers	13274
pixels	13289
the area	13299
damaged tissue and the number of pixels in the whole segment -LSB- 20 -RSB-	13311
damaged tissue	13311
the number of pixels in the whole segment -LSB- 20 -RSB-	13330
the number	13330
pixels in the whole segment -LSB- 20 -RSB-	13344
pixels	13344
the whole segment -LSB- 20 -RSB-	13354
the whole segment	13354
20 -RSB-	13373
Statistical analysis .	13378
All statistical analyses	13400
standard statistics computer software -LRB- SPSS 11.5 for Windows -RRB-	13443
standard statistics computer software	13443
SPSS 11.5 for Windows	13482
SPSS 11.5	13482
Windows	13496
One-way ANOVA followed by Tukey 's post hoc test	13506
One-way ANOVA	13506
Tukey 's post hoc test	13532
Tukey 's	13532
statistical differences between the spared tissue and myelin ratio in each group	13576
statistical differences	13576
the spared tissue and myelin ratio in each group	13608
the spared tissue	13608
myelin ratio in each group	13630
myelin ratio	13630
each group	13646
BBB scores	13658
groups	13689
non-parametric analysis	13702
Kruskal-Wallis followed by Mann - Whitney U test	13727
Kruskal-Wallis	13727
Mann - Whitney U test	13754
Mann	13754
Whitney U test	13760
Whitney U	13760
test	13770
Cell numbers	13777
spinal cord	13793
transplanted groups -LRB- OEC vs co-transplant and ESMN vs co-transplant -RRB-	13808
transplanted groups	13808
OEC	13829
vs co-transplant and ESMN vs co-transplant	13833
co-transplant and ESMN	13836
co-transplant	13862
independent t-test	13896
A statistically significant difference	13916
P	13971
RESULTS Table 1 .	13980
RESULTS	13980
Table 1	13988
Specific primers	13997
PCR amplification	14023
Fig. 1 .	14043
Fig.	14043
1	14048
-LRB- A -RRB- Olfactory ensheathing	14051
A	14052
cells expressing p75	14077
cells	14077
p75	14094
-LRB- B -RRB- multiple neurites	14099
-LRB- B -RRB-	14099
multiple neurites	14103
neuronal cells emerging from aggregate	14125
neuronal cells	14125
aggregate	14154
Immunostaining of aggregates	14165
Immunostaining	14165
aggregates	14183
antibody	14214
Tubulin Î²III and -LRB- C -RRB- microtubule assassination protein 2 -LRB- D -RRB-	14231
Tubulin Î²III	14231
C	14249
microtubule assassination protein 2 -LRB- D -RRB-	14252
-LRB- E -RRB-	14293
The expression	14297
several neuronal genes in undifferentiated ES cells as negative cell control	14315
several neuronal genes	14315
undifferentiated ES cells as negative cell control	14341
undifferentiated ES cells	14341
negative cell control	14370
CGR8	14393
mouse spinal cord as positive control and RA + Shh treated	14400
mouse spinal cord as positive control and RA	14400
mouse spinal cord	14400
positive control and RA	14421
Shh treated	14447
Shh	14447
Fig. 2 .	14461
Fig.	14461
2	14466
-LRB- A -RRB- BBB scores for five groups .	14469
-LRB- A -RRB-	14469
BBB scores for five groups	14473
BBB scores	14473
five groups	14488
Animals	14501
contusion injury	14518
Day 0	14538
Transplants	14545
Day 9	14570
BBB scores of groups receiving transplants	14577
BBB scores	14577
groups receiving transplants	14591
groups	14591
transplants	14608
control and medium-injected groups	14654
-LRB- B -RRB- Percentage of	14690
-LRB- B -RRB-	14690
tissue and myelinated area in five groups	14715
tissue and myelinated area	14715
five groups	14745
The OEC + ESMN group	14758
The OEC	14758
ESMN group	14768
a significantly greater percentage	14783
spared tissue and myelinated area than other groups	14821
spared tissue	14821
myelinated area than other groups	14839
myelinated area	14839
other groups	14860
Bar graphs	14878
the cell counts	14894
The number of GFP-positive cells in the OEC + ESMN groups	14911
The number	14911
GFP-positive cells in the OEC + ESMN groups	14925
GFP-positive cells	14925
the OEC + ESMN groups	14947
the OEC	14947
ESMN groups	14957
that in the ESMN group	14999
that	14999
the ESMN group	15007
Fig. 3 .	15024
Fig.	15024
3	15029
Photomicrographs	15032
longitudinal sections	15052
the spinal cord	15077
the control group -LRB- A and B -RRB-	15096
the control group	15096
A and B	15115
A	15115
B	15121
the mediuminjected group -LRB- C and D -RRB-	15131
the mediuminjected group	15131
C and D	15157
C	15157
D	15163
4 weeks	15166
second surgery	15180
Slides	15196
Luxol fast blue -LRB- A and C -RRB- and silver nitrate -LRB- B and D -RRB-	15222
Luxol fast blue -LRB- A and C -RRB-	15222
Luxol	15222
A and C	15239
A	15239
C	15245
silver nitrate -LRB- B and D -RRB-	15252
silver nitrate	15252
B and D	15268
B	15268
D	15274
Large cystic cavities	15278
the injured area -LRB- Stars -RRB-	15310
the injured area	15310
Stars	15328
The white matter injury	15336
Luxol fast blue	15381
Luxol	15381
Arrows	15398
damaged area	15410
Fig. 4 .	15425
Fig.	15425
4	15430
Photomicrographs	15433
longitudinal sections	15453
the spinal cord in the OEC group 4 weeks	15478
the spinal cord	15478
the OEC group	15497
4 weeks	15511
OEC transplantation	15525
OEC -LRB- A , stars -RRB-	15561
OEC	15561
A , stars	15566
A	15566
stars	15569
myelin -LRB- B and C stained by Luxol fast blue , arrows -RRB-	15585
myelin	15585
B and C stained by Luxol fast blue , arrows	15593
B and C	15593
Luxol fast blue , arrows	15612
Luxol fast blue	15612
Luxol	15612
arrows	15629
Presence	15638
neuronal processes	15650
silver nitrate staining -LRB- D , arrows -RRB-	15672
silver nitrate staining	15672
D , arrows	15697
D	15697
arrows	15700
Fig. 5 .	15710
Fig.	15710
5	15715
Photomicrographs	15718
longitudinal sections	15738
the spinal cord in the ESMN group 4 weeks	15763
the spinal cord	15763
the ESMN group	15782
4 weeks	15797
transplantation	15811
GFP-positive cells -LRB- A , arrows -RRB-	15828
GFP-positive cells	15828
A , arrows	15848
A	15848
arrows	15851
spinal cord and established neuronal network	15871
spinal cord	15871
established neuronal network	15887
area	15928
OEC and OEC + ESMN groups -LRB- B , stained by Luxol fast blue -RRB-	15948
OEC	15948
OEC + ESMN groups -LRB- B , stained by Luxol fast blue -RRB-	15956
OEC + ESMN groups	15956
B , stained by Luxol fast blue	15975
B	15975
Luxol fast blue	15989
Luxol	15989
Neuronal network	16007
silver nitrate	16035
C , arrows	16051
C	16051
arrows	16054
OEC cell culture .	16064
OEC	16064
cell culture	16068
p75	16085
a receptor found on the external surface of the plasma membranes of OEC	16092
a receptor	16092
the external surface of the plasma membranes of OEC	16112
the external surface	16112
the plasma membranes of OEC	16136
the plasma membranes	16136
OEC	16160
the purity of the cell cultures and number of OEC obtained	16165
the purity	16165
the cell cultures and number of OEC obtained	16179
the cell cultures and number	16179
OEC obtained	16211
OEC	16211
the immunofluorescently labeled cell types	16252
the	16252
cell types	16284
The purity of OEC culture by this separation procedure	16296
The purity	16296
OEC culture by this separation procedure	16310
OEC culture	16310
this separation procedure	16325
95 % -LRB- Fig. 1A -RRB-	16355
95 %	16355
Fig. 1A	16360
ES cell differentiation .	16370
ES	16370
cell differentiation	16373
Two days after partial trypsinization of treated EB , many of aggregates	16395
Two days	16395
partial trypsinization of treated EB , many of aggregates	16410
partial trypsinization	16410
EB , many of aggregates	16444
EB	16444
many of aggregates	16448
many	16448
aggregates	16456
extensive outgrowth of neuritis	16476
extensive outgrowth	16476
neuritis	16499
Neurite outgrowth	16509
many points	16537
the perimeter	16555
aggregate forming a dense , tangled collection of neuritis -LRB- Fig. 1B -RRB-	16572
aggregate	16572
a dense , tangled collection of neuritis -LRB- Fig. 1B -RRB-	16590
a dense , tangled collection	16590
neuritis -LRB- Fig. 1B -RRB-	16621
neuritis	16621
Fig. 1B	16631
the neuron-like cells and process	16666
neuronassociated proteins	16708
cultures	16735
antibodies to class III Î²-tubulin and MAP2 -LRB- Fig. 1C and D -RRB-	16762
antibodies to class III Î²-tubulin	16762
antibodies	16762
class III Î²-tubulin	16776
MAP2 -LRB- Fig. 1C and D -RRB-	16800
MAP2	16800
Fig. 1C and D	16806
Fig. 1C	16806
D	16818
expression of neuronal gene	16838
expression	16838
neuronal gene	16852
ES cultures	16884
we	16897
the expression	16909
Olig2 , Pax6 , Nkx6 .1 , Isl1 , Isl2 , Hb9 , Lim1 , Lim2 , GFAP and OMG	16927
Olig2	16927
Pax6	16934
Nkx6 .1	16940
Isl1 , Isl2 , Hb9 , Lim1 , Lim2 , GFAP and OMG	16948
RT-PCR -LRB- Fig. 1E -RRB-	16993
RT-PCR	16993
Fig. 1E	17001
The results	17011
motor neuron progenitor markers -LRB- Olig2 , Nkx6 .1 and Pax6 -RRB-	17037
motor neuron progenitor markers	17037
Olig2 , Nkx6 .1 and Pax6	17070
Olig2	17070
Nkx6 .1 and Pax6	17077
the expression of Pax6 and Olig2	17113
the expression	17113
Pax6 and Olig2	17131
that of Nkx6 .1	17162
that	17162
Nkx6 .1	17170
Motor neuron markers -LRB- Isl1 , Isl2 and Hb9 -RRB-	17178
Motor neuron markers	17178
Isl1 , Isl2 and Hb9	17200
Isl1	17200
Isl2 and Hb9	17206
expression of Isl1 and Hb9	17240
expression	17240
Isl1 and Hb9	17254
that of Isl2	17283
that	17283
Isl2	17291
Interneuron markers -LRB- Lim1 and Lim2 -RRB-	17297
Interneuron markers	17297
Lim1 and Lim2	17318
Lim1	17318
Lim2	17327
Lim1	17352
a higher expression	17361
Astrocyte -LRB- GFAP -RRB- and oligodendrocyte -LRB- OMG -RRB- markers	17382
Astrocyte -LRB- GFAP -RRB-	17382
Astrocyte	17382
GFAP	17393
oligodendrocyte -LRB- OMG -RRB- markers	17403
oligodendrocyte	17403
OMG	17420
markers	17425
low levels	17451
Recovery of hindlimb function .	17463
Recovery	17463
hindlimb function	17475
BBB score	17494
three and nine days post injury and at weekly intervals	17517
three and nine days	17517
weekly intervals	17556
day 9	17586
the same day	17596
animals	17610
transplantation	17649
The criteria for inclusion in this study	17666
The criteria	17666
inclusion in this study	17683
inclusion	17683
this study	17696
the animal	17717
0-2	17739
day nine	17746
Figure 2A	17756
average BBB scores	17778
the post injury and post transplantation period	17804
There	17853
no significant difference in average BBB scores	17863
no significant difference	17863
average BBB scores	17892
transplantation among 5 groups -LRB- P > 0.05 -RRB-	17920
transplantation	17920
5 groups -LRB- P > 0.05 -RRB-	17942
5 groups	17942
P > 0.05	17952
P	17952
> 0.05	17953
>	17953
0.05	17954
transplantation	17971
a significant recovery of hindlimb function	17988
a significant recovery	17988
hindlimb function	18014
rats	18048
the transplanted groups	18056
medium-injected and control groups -LRB- P < 0.05 -RRB-	18094
medium-injected and control groups	18094
P < 0.05	18130
P	18130
< 0.05	18131
<	18131
0.05	18132
The mean recovery score in OEC , ESMN and OEC + ESMN groups	18139
The mean recovery score	18139
OEC , ESMN and OEC + ESMN groups	18166
OEC	18166
ESMN	18171
OEC + ESMN groups	18180
4 weeks	18198
transplantation	18212
7.33 Â±	18233
1.03	18240
range 7-9	18246
,7.5 Â± 0.83 -LRB- range 7-9 -RRB-	18256
,7.5 Â± 0.83	18256
,7.5	18256
0.83	18263
range 7-9	18269
8.5 Â± 1.2 -LRB- range 7-10 -RRB-	18281
8.5 Â± 1.2	18281
8.5	18281
1.2	18287
range 7-10	18292
the corresponding score in the control and medium-injected groups	18322
the corresponding score	18322
the control and medium-injected groups	18349
the control	18349
medium-injected groups	18365
0.4 Â± 0.53	18393
0.4	18393
0.53	18399
range 0-1	18405
0.66	18420
0.57	18427
range 0-1	18433
There	18445
no significant difference	18455
transplanted groups four weeks after transplantation	18489
transplanted groups	18489
four weeks	18509
transplantation	18526
Histological evaluation .	18543
Longitudinal sections of the injured animals	18568
Longitudinal sections	18568
the injured animals	18593
edema , inflammation and loss of normal tissue architecture	18620
edema , inflammation and loss	18620
normal tissue architecture	18652
the site of injury	18683
the site	18683
injury	18695
several cavities	18703
portions of the gray and white matters , surrounded by scar tissue	18749
portions	18749
the gray and white matters , surrounded by scar tissue	18761
the gray and white matters	18761
scar tissue	18803
this study	18819
axonal damage and gliosis	18831
axonal damage	18831
gliosis	18849
The extent of tissue damage	18871
The extent	18871
tissue damage	18885
the control and medium-injected groups	18918
the control	18918
medium-injected groups	18934
other groups -LRB- Fig 3-6 -RRB-	18962
other groups	18962
Fig 3-6	18976
Spinal tissue sparing	18986
the damaged area -LRB- including degenerate tissue and transplanted cells -RRB-	19028
the damaged area	19028
degenerate tissue and transplanted cells	19056
degenerate tissue	19056
transplanted cells	19078
spinal cord segment	19101
the control -LRB- 27.95 Â± 3.52 -RRB-	19125
the control	19125
27.95 Â± 3.52	19138
27.95	19138
3.52	19146
medium-injected groups -LRB- 29.33 Â± 4.04 -RRB- of the spinal cord	19156
medium-injected groups -LRB- 29.33 Â± 4.04 -RRB-	19156
medium-injected groups	19156
29.33 Â± 4.04	19180
29.33	19180
4.04	19188
the spinal cord	19197
the segment examined	19214
the segment	19214
contrast	19250
significantly more spinal tissue -LRB- P < 0.001 -RRB-	19260
significantly more spinal tissue	19260
P < 0.001	19294
P	19294
< 0.001	19295
<	19295
0.001	19296
OEC -LRB- 63.95 Â± 17.09 -RRB-	19317
OEC	19317
63.95 Â± 17.09	19322
63.95	19322
17.09	19330
ESMN -LRB- 70.93 Â± 5.62 -RRB-	19338
ESMN	19338
70.93 Â± 5.62	19344
70.93	19344
5.62	19352
OEC + ESMN -LRB- 82.07 Â± 7.83 -RRB- groups -LRB- Fig. 2B -RRB-	19362
OEC + ESMN -LRB- 82.07 Â± 7.83 -RRB- groups	19362
OEC	19362
ESMN -LRB- 82.07 Â± 7.83 -RRB- groups	19368
ESMN -LRB- 82.07 Â± 7.83 -RRB-	19368
ESMN	19368
82.07 Â± 7.83	19374
82.07	19374
7.83	19382
groups	19388
Fig. 2B	19396
No significant differences in percentage of spared tissue	19406
No significant differences	19406
percentage of spared tissue	19436
percentage	19436
spared tissue	19450
control and medium-injected groups or OEC and ESMN groups	19483
control and medium-injected groups	19483
OEC and ESMN groups	19521
The OEC + ESMN group	19542
The OEC	19542
ESMN group	19552
a significantly greater percentage	19567
spared tissue than other groups -LRB- P < 0.05 -RRB-	19605
spared tissue	19605
other groups -LRB- P < 0.05 -RRB-	19624
other groups	19624
P < 0.05	19638
P	19638
< 0.05	19639
<	19639
0.05	19640
The ESMN group	19647
a greater percentage of myelinated area	19666
a greater percentage	19666
myelinated area	19690
control and medium-injected groups	19711
there	19751
no significant difference	19761
The percentage of myelinated area	19788
The percentage	19788
myelinated area	19806
OEC group than control , medium-injected and ESMN groups	19837
OEC group	19837
control , medium-injected and ESMN groups	19852
P < 0.05	19894
P	19894
< 0.05	19895
<	19895
0.05	19896
The OEC + ESMN group	19903
The OEC	19903
ESMN group	19913
a significantly greater percentage of myelinated area	19928
a significantly greater percentage	19928
myelinated area	19966
other groups -LRB- P < 0.05 -RRB- -LRB- Fig. 2B -RRB-	19987
other groups -LRB- P < 0.05 -RRB-	19987
other groups	19987
P < 0.05	20001
P	20001
< 0.05	20002
<	20002
0.05	20003
Fig. 2B	20010
cell counts	20031
we	20044
the number	20055
transplanted cells	20069
the longitudinal sections	20091
Hoechst-labeled cells	20120
Figs. 4A and 6B-D	20143
Figs. 4A	20143
6B-D	20156
GFPpositive	20166
Figs. 5A and 6A , 6C and 6D	20179
Figs. 5A	20179
6A , 6C and 6D	20192
We	20208
transplant GFP-positive and Hoechst-labeled cells	20230
the cavity	20287
tissue of the spinal cord	20309
tissue	20309
the spinal cord	20319
OEC and OEC + ESMN groups	20339
OEC	20339
OEC + ESMN groups	20347
many of the OEC	20366
many	20366
the OEC	20374
the cystic cavity	20414
the average numbers of cells	20437
the average numbers	20437
cells	20460
28524	20471
7287 in OEC and 26702 Â± 12120	20479
7287 in OEC	20479
7287	20479
OEC	20487
26702 Â± 12120	20495
26702	20495
12120	20503
OEC + ESMN groups	20512
OEC	20512
ESMN groups	20518
ESMN and OEC + ESMN groups	20534
ESMN	20534
OEC + ESMN groups	20543
the numbers of GFP-positive cells	20562
the numbers	20562
GFP-positive cells	20577
5348 Â± 2125 and 9362 Â± 2783	20601
5348 Â± 2125 and 9362	20601
5348	20601
2125 and 9362	20608
2783	20624
Fig. 2C	20644
There	20654
a significant difference	20664
cell number in OEC and ESMN groups -LRB- P < 0.001 -RRB-	20697
cell number	20697
OEC and ESMN groups -LRB- P < 0.001 -RRB-	20712
OEC and ESMN groups	20712
P < 0.001	20733
P	20733
< 0.001	20734
<	20734
0.001	20735
The Hoechst-labeled cells in OEC and OEC + ESMN	20743
The Hoechst-labeled cells	20743
OEC and OEC + ESMN	20772
OEC and OEC	20772
ESMN	20786
P > 0.05	20825
P	20825
> 0.05	20826
>	20826
0.05	20827
The numbers of GFP-positive cells in OEC + ESMN	20834
The numbers	20834
GFP-positive cells in OEC + ESMN	20849
GFP-positive cells	20849
OEC + ESMN	20871
OEC	20871
ESMN	20877
those of ESMN group -LRB- P < 0.05 -RRB-	20913
those	20913
ESMN group -LRB- P < 0.05 -RRB-	20922
ESMN group	20922
P < 0.05	20934
P	20934
< 0.05	20935
<	20935
0.05	20936
DISCUSSION Most SCI research	20944
DISCUSSION	20944
Most SCI research	20955
restoration	20984
white matter	20999
tracts -LRB- regeneration -RRB-	21017
tracts	21017
regeneration	21025
cellular replacement -LRB- neuronal or oligodendrocyte -RRB-	21043
cellular replacement	21043
neuronal or oligodendrocyte	21065
neuronal	21065
oligodendrocyte	21077
The most frequently used cell for white matter regeneration	21095
The most frequently used cell	21095
white matter regeneration	21129
OEC	21158
The results of this study	21163
The results	21163
this study	21178
OEC	21207
histological and functional recovery	21219
transplantation	21262
OEC group	21282
the sparing and myelination of spinal tissue	21293
the sparing and myelination	21293
spinal tissue	21324
cavity formation	21352
The mean BBB score in OEC group	21380
The mean BBB score	21380
OEC group	21402
control and medium-injected groups	21428
Several studies	21464
OEC transplantation	21500
promise	21526
a potential therapy for SCI	21537
a potential therapy	21537
SCI	21561
other studies	21575
OEC	21609
-LSB- 21 , 22 -RSB-	21642
Comparison of studies	21652
Comparison	21652
studies	21666
a multitude of approaches	21695
a multitude	21695
approaches	21710
different research groups	21724
example	21755
the various purification strategies and criteria used for defining OEC	21764
the various purification strategies and criteria	21764
OEC	21831
5 -RSB-	21836
the most successful experiments	21843
adult rats	21876
OEC transplants	21901
ability and sensorimotor reflexes	21936
complete spinal cord transaction -LSB- 23 -RSB- ,	21976
complete spinal cord transaction	21976
23 -RSB-	22010
respiratory function	22025
cervical hemisection -LSB- 24 -RSB- and bladder control	22052
cervical hemisection	22052
24 -RSB-	22074
bladder control	22082
lumbosacral dorsal root transaction -LSB- 25 -RSB-	22104
lumbosacral dorsal root transaction	22104
25 -RSB-	22141
This functional recovery	22146
anatomical and activity-based regeneration	22187
the associated axon tracts , including long distance regrowth of some axons	22233
the associated axon tracts	22233
long distance regrowth of some axons	22271
long distance regrowth	22271
some axons	22297
-LSB- 5 , 6 , 23 , 25 , 26 -RSB-	22308
Improvement of BBB score in previous	22328
Improvement	22328
BBB score in previous	22343
BBB score	22343
previous	22356
present research	22380
OEC	22409
profound effects	22417
corticospinal and other tracts involved in rat hindlimb movement	22437
corticospinal and other tracts	22437
rat hindlimb movement	22480
The effects of OEC on SCI	22503
The effects	22503
OEC on SCI	22518
OEC	22518
SCI	22525
nature of this cell	22540
nature	22540
this cell	22550
OEC	22561
several molecules	22573
axonal growth including NGF , BDNF , GDNF , and NT-4 / 5 -LSB- 5 , 6 -RSB-	22617
axonal growth	22617
NGF , BDNF , GDNF , and NT-4 / 5 -LSB- 5 , 6 -RSB-	22641
NGF	22641
BDNF	22646
GDNF	22652
NT-4 / 5 -LSB- 5 , 6 -RSB-	22662
NT-4	22662
5 -LSB- 5 , 6	22667
5	22667
-LSB- 5 , 6	22669
Reports	22677
OEC	22700
axonal regeneration	22744
a transplant	22780
it	22810
the white matter tracts of the host spinal cord	22818
the white matter tracts	22818
the host spinal cord	22845
Such regeneration	22867
several fiber types	22902
corticospinal , dorsal column and monoaminergic fibers -LSB- 6 -RSB-	22932
corticospinal	22932
dorsal column	22947
monoaminergic fibers -LSB- 6 -RSB-	22965
monoaminergic fibers	22965
6 -RSB-	22987
The increase in tissue sparing in the present study	22991
The increase	22991
tissue sparing in the present study	23007
tissue sparing	23007
the present study	23025
the promotion of axonal regeneration and extracellular matrix production	23059
the promotion	23059
axonal regeneration and extracellular matrix production	23076
axonal regeneration	23076
extracellular matrix production	23100
OEC transplantation	23138
Improvement of BBB	23159
Improvement	23159
BBB	23174
regeneration of axons	23199
regeneration	23199
axons	23215
establishment of new synaptic connections	23239
establishment	23239
new synaptic connections	23256
myelin sheath	23295
efficient propagation of action potentials	23319
efficient propagation	23319
action potentials	23344
OEC transplanted from rats into demyelinating lesions in the rat spinal cord	23363
OEC	23363
rats	23385
lesions	23409
the rat spinal cord	23420
remyelination of axons	23449
remyelination	23449
axons	23466
impulse conduction	23485
-LSB- 7 , 27 , 28 -RSB-	23504
Sasaki et al. -LSB- 29 -RSB-	23517
Sasaki et al. -LSB-	23517
transplantation of OEC expressing green fluorescent protein	23548
transplantation	23548
OEC expressing green fluorescent protein	23567
OEC	23567
green fluorescent protein	23582
transplanted cells	23623
about 50 % of the peripheral-type myelin around regenerating axons	23654
about 50 %	23654
the peripheral-type myelin around regenerating axons	23667
the peripheral-type myelin	23667
regenerating axons	23701
the remainder	23727
Schwann cells	23760
the transplant -LSB- 29 -RSB-	23787
the transplant	23787
29 -RSB-	23803
SCI	23814
most of the affected cells	23819
most	23819
the affected cells	23827
12 hours	23857
a delayed phase of cell death	23876
a delayed phase	23876
cell death	23895
several days or weeks	23919
Cell death	23942
the gray matter of the cord first	23963
the gray matter	23963
the cord first	23982
the cord	23982
the bodies of nerve cells	24004
the bodies	24004
nerve cells	24018
30 -RSB-	24038
we	24054
ES cells	24077
replacement of dead cells	24090
replacement	24090
dead cells	24105
the present study	24120
we	24139
ES cells	24152
a motor neuron fate	24164
transplantation	24191
the expression of motor neuron progenitor , motor neuron and interneuron markers	24221
the expression	24221
motor neuron progenitor , motor neuron and interneuron markers	24239
transplantation	24308
The result of this study	24325
The result	24325
this study	24339
the motor neuron progenitor markers -LRB- Pax6 , Nkx6 .1 and olig2 -RRB-	24362
the motor neuron progenitor markers	24362
Pax6 , Nkx6 .1 and olig2	24399
Pax6	24399
Nkx6 .1 and olig2	24405
ventral motor neuron markers -LRB- HB9 , Isl1and Isl2 -RRB-	24427
ventral motor neuron markers	24427
HB9 , Isl1and Isl2	24457
HB9	24457
Isl1and Isl2	24462
Our results	24492
interneuron markers Lim1 and Lim2	24518
interneuron markers	24518
Lim1 and Lim2	24538
cells	24585
This	24592
accordance with the results of previous researchers -LSB- 10 -RSB-	24603
accordance	24603
the results of previous researchers -LSB- 10 -RSB-	24619
the results	24619
previous researchers -LSB- 10 -RSB-	24634
previous researchers	24634
10 -RSB-	24656
the presence of RA	24664
the presence	24664
RA	24680
ES cells	24684
class I neural gene like Pax6 , irx3 , dbx1 and Pax7 in high levels	24701
class I neural gene	24701
class I	24701
Pax6 , irx3 , dbx1 and Pax7	24726
high levels	24755
class II like Nkx6 .1 and Olig2	24771
class II	24771
Nkx6 .1 and Olig2	24785
low levels	24805
This profile of transcription factor expression	24817
This profile	24817
transcription factor expression	24833
interneuron progenitors -LSB- 31 -RSB-	24886
interneuron progenitors	24886
31 -RSB-	24911
The induction of motor neuron progenitors	24916
The induction	24916
motor neuron progenitors	24933
Shh activity -LSB- 10 -RSB-	24969
Shh activity	24969
10 -RSB-	24983
Shh	24995
EB	25002
class II genes	25015
class	25015
II genes	25021
the expression of Pax7	25042
the expression	25042
Pax7	25060
transplantation of differentiated ES cells	25072
transplantation	25072
ES cells	25106
the tissue sparing and BBB	25116
the tissue sparing	25116
BBB	25139
cavity ratio	25163
to control and medium-injected groups	25195
medium-injected groups	25210
There	25234
no significant difference	25244
tissue sparing , cavity ratio and BBB score	25278
tissue sparing	25278
cavity ratio	25294
BBB score	25311
OEC and ESMN groups	25324
myelin ratio in OEC group	25348
myelin ratio	25348
OEC group	25364
Our results	25386
many ESMN	25410
transplantation	25430
some of them	25451
some	25451
them	25459
the cavity	25469
spinal cord and established neuronal network	25496
spinal cord	25496
established neuronal network	25512
McDonald and Howard -LSB- 32 -RSB-	25542
McDonald and Howard	25542
32 -RSB-	25563
the same result	25574
transplantation of ES derived neuronal cells	25596
transplantation	25596
ES derived neuronal cells	25615
ES	25615
neuronal cells	25626
Other researchers	25642
ESMN for brain damage	25665
ESMN	25665
brain damage	25674
the grafted cells	25702
the implantation site	25747
substantial migration	25789
the damaged lesion in a directed manner up to the cortical region	25829
the damaged lesion	25829
a directed manner up to the cortical region	25851
a directed manner	25851
the cortical region	25875
They	25896
the transplanted neurons	25916
the recipient neurons	25957
a neural network -LSB- 33 -RSB-	25987
a neural network	25987
33 -RSB-	26005
Partial recovery	26010
paralysis after transplantation of mES cells treated with Shh and RA	26032
paralysis	26032
transplantation of mES cells treated with Shh and RA	26048
transplantation	26048
mES cells treated with Shh and RA	26067
mES cells	26067
Shh and RA	26090
2 -RSB-	26115
other researchers	26128
transplantation	26157
apoptosis	26176
cells derived from KD3 line into the injured spinal cord	26211
cells	26211
KD3 line	26230
the injured spinal cord	26244
locomotor recovery	26284
tumor-like growth	26314
cells , accompanied by increased debilitation , morbidity and mortality	26335
cells	26335
increased debilitation , morbidity and mortality	26357
Our results	26406
increase in tissue sparing	26433
increase	26433
tissue sparing	26445
1 -RRB- transplanted motor	26477
neuron and other cell types	26499
cell mixture	26530
neural network	26557
endogenous neural progenitors	26576
3 -RRB- extracellular matrix produced by progenitors	26610
extracellular matrix	26613
progenitors	26646
ES cells -LSB- 30 -RSB-	26671
ES cells	26671
30 -RSB-	26681
Previous researchers	26686
neural progenitors that are endogenous to the central nervous system	26726
neural progenitors	26726
the central nervous system	26768
progenitors derived from ES cells	26796
progenitors	26796
ES cells	26821
considerable quantities	26838
extracellular matrix like laminin and fibronectin	26865
extracellular matrix	26865
laminin and fibronectin	26891
30 -RSB-	26916
The myelin ratio	26921
the ESMN group	26953
control and medium-injected groups	26982
there	27022
no significant difference	27032
The low levels of myelination	27059
The low levels	27059
myelination	27077
small number of oligodendrocyte differentiated by action of RA on ES cells	27108
small number	27108
oligodendrocyte differentiated by action of RA on ES cells	27124
oligodendrocyte	27124
action of RA	27158
action	27158
RA	27168
ES cells	27174
The previous reports	27184
ES	27222
oligodendrocytes	27237
injured spinal cord -LSB- 30 -RSB-	27270
injured spinal cord	27270
30 -RSB-	27291
We	27296
the mean of Hoechst-labeled cells in OEC group	27315
the mean	27315
Hoechst-labeled cells in OEC group	27327
Hoechst-labeled cells	27327
OEC group	27352
GFP-positive cells in ESMN group	27393
GFP-positive cells	27393
ESMN group	27415
The reduction of GFP-positive cells	27427
The reduction	27427
GFP-positive cells	27444
the injured environment and rejection	27479
the injured environment	27479
rejection	27507
transplantation	27523
Many ESMN	27540
transplantation	27560
some of them	27581
some	27581
them	27589
neuronal network	27619
Previous researchers	27637
only few of ESMN	27673
only few	27673
ESMN	27685
axons	27699
the peripheral nervous system	27710
the survival rate of these cells in spinal cord	27749
the survival rate	27749
these cells in spinal cord	27770
these cells	27770
spinal cord	27785
-LSB- 10 , 11 -RSB-	27811
Shukla et al. -LSB- 34 -RSB-	27821
Shukla et al. -LSB-	27821
transplantation	27852
neural stem cell	27871
the mesencephalic region of brain	27894
the mesencephalic region	27894
brain	27922
dopamine neurons	27937
low survival of cells , limited host-graft interaction and poor axonal outgrowth	27973
low survival	27973
cells , limited host-graft interaction and poor axonal outgrowth	27989
cells	27989
limited host-graft interaction	27996
poor axonal outgrowth	28031
They	28054
the co-transplantation	28069
OEC and neural stem cell	28095
the mesencephalic region of brain	28126
the mesencephalic region	28126
brain	28154
dopamine neuron	28169
the presence of OEC	28207
the presence	28207
OEC	28223
survival of neural stem	28251
survival	28251
neural stem	28263
cell-derived dopamine neurons	28275
axonal fiber outgrowth and restitution	28306
motor function recovery	28348
the co-transplanted group	28388
the present study	28418
we	28437
the effect of cotransplantation of ESMN and OEC	28450
the effect	28450
cotransplantation of ESMN and OEC	28464
cotransplantation	28464
ESMN and OEC	28485
We	28499
the lost neurons	28520
ESMN	28571
the OEC	28583
the survival of transplanted ESMN	28606
the survival	28606
transplanted ESMN	28622
NTF and cell adhesion molecules	28657
The results	28690
tissue sparing and myelin ratio	28714
tissue sparing	28714
myelin ratio	28733
other groups	28763
This finding	28777
the synergistic effects of two cell types	28806
the synergistic effects	28806
two cell types	28833
spinal cord	28864
The survival rate of GFPpositive cells in co-transplanted group	28877
The survival rate	28877
GFPpositive cells in co-transplanted group	28898
GFPpositive cells	28898
co-transplanted group	28919
ESMN group	28960
This	28972
the first report of positive effects of OEC on survival rate of ESMN	28980
the first report	28980
positive effects of OEC on survival rate of ESMN	29000
positive effects	29000
OEC on survival rate of ESMN	29020
OEC	29020
survival rate of ESMN	29027
survival rate	29027
ESMN	29044
This	29050
GFP-positive cells in the spinal cord	29064
GFP-positive cells	29064
the spinal cord	29086
the existence	29111
functional graft at transplantation site	29128
functional graft	29128
transplantation site	29148
the higher survival of ESMN neurons in graft itself	29191
the higher survival	29191
ESMN neurons in graft itself	29214
ESMN neurons	29214
graft	29230
possible resprouting of intrinsic neurons in response	29254
possible resprouting	29254
intrinsic neurons in response	29278
intrinsic neurons	29278
response	29299
various NTF including NGF , secreted by OEC	29311
various NTF	29311
NGF , secreted by OEC	29333
NGF	29333
OEC	29350
contact-mediated support of OEC to residual axonal fibers	29365
contact-mediated support	29365
OEC to residual axonal fibers	29393
OEC	29393
residual axonal fibers	29400
NGF	29430
dual activity	29439
NTF support	29466
properties of antioxidant -LSB-	29489
properties	29489
antioxidant -LSB-	29503
35 -RSB- , anti-apoptotic -LSB- 36 -RSB- , and neurorescue activity	29516
35 -RSB-	29516
anti-apoptotic -LSB- 36 -RSB- , and neurorescue activity	29521
anti-apoptotic -LSB- 36 -RSB-	29521
anti-apoptotic -LSB-	29521
neurorescue activity	29546
OEC	29568
olfactory bulb , release NTFs such as NGF	29585
olfactory bulb	29585
release NTFs such as NGF	29601
release NTFs	29601
NGF	29622
GDNF , BDNF , NT-4	29627
GDNF , BDNF ,	29627
NT-4	29639
5 , CNTF and FGF2 -LSB- 5 , 6 -RSB-	29644
5	29644
CNTF and FGF2	29647
5	29662
6 -RSB-	29665
NGF	29669
the number of dopamine neurons in lesioned nigral region and graft	29693
the number	29693
dopamine neurons in lesioned nigral region and graft	29707
dopamine neurons	29707
lesioned nigral region and graft	29727
37 -RSB- , increase synapse formation	29761
37 -RSB-	29761
increase synapse formation	29766
neuronal path finding	29808
the expression	29843
cell adhesion molecules	29861
nerve cells	29888
guiding axons in establishing connectivity with host cells -LSB- 38 -RSB-	29905
guiding axons	29905
connectivity	29935
host cells -LSB- 38 -RSB-	29953
host cells	29953
38 -RSB-	29965
We	29970
increased survival of transplanted cells in the co-transplanted group	29990
increased survival	29990
transplanted cells in the co-transplanted group	30012
transplanted cells	30012
the co-transplanted group	30034
the expression	30085
neural cell adhesion molecules , L1 and growth associated proteins	30103
neural cell adhesion molecules	30103
L1	30135
growth associated proteins	30142
OEC	30172
synapse formation and neuronal path finding	30193
synapse formation	30193
neuronal path finding	30215
guiding axons in making connections -LSB- 38 -RSB-	30240
guiding axons	30240
connections -LSB- 38 -RSB-	30264
connections	30264
38 -RSB-	30277
The BBB score	30282
ESMN and OEC groups	30321
The authors	30342
transplanted neurons	30367
more functional synaptic connections	30409
the length of study	30449
the length	30449
study	30463
hindlimb improvement	30491
Therapeutic use of stem cells to regenerate motor neurons in the spinal cord	30513
Therapeutic use	30513
stem cells	30532
motor neurons	30557
the spinal cord	30574
a method	30599
cell survival	30625
extended periods of time	30643
extended periods	30643
time	30663
axons	30682
the white matter toward muscle targets	30696
the white matter	30696
muscle targets	30720
We	30736
the cotransplantation of ESMN and OEC into an injured spinal cord	30755
the cotransplantation	30755
ESMN and OEC into an injured spinal cord	30780
ESMN and OEC	30780
an injured spinal cord	30798
a synergistic effect	30826
neural regeneration , ESMN survival and functional recovery	30858
neural regeneration	30858
ESMN survival	30879
functional recovery	30897
we	30929
a new strategy	30944
treatment of SCI	30963
treatment	30963
SCI	30976
co-transplantation of ESMN and OEC	30983
co-transplantation	30983
ESMN and OEC	31005
